

CS/BSE/NSE/PR/2016-2017
July 21, 2016

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

Stock Code: SUVEN - EQ

Stock Code: 530239

Dear Sir/Madam,

Sub: Press Release

.....

With reference to above subject, please find enclosed Press Release of our company titled **“SUVEN’S Pashamylaram’s Unit Successfully completes US FDA Inspection”**

This is for your information and records

Thanking You,
Yours faithfully,
For **Suven Life Sciences Limited**



K. Hanumantha Rao
Company Secretary

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com

News Release

SUVEN'S Pashamylaram's Unit Successfully completes US FDA Inspection

HYDERABAD, INDIA (July 21, 2016) – Suven Life Sciences Limited an ISO 9001, ISO 14001 and OHSAS 18001 company has undergone US FDA renewal inspection at their facility in Pashamylaram near Hyderabad for the manufacture and supply of active pharmaceutical ingredients (bulk drugs), intermediates and formulations under cGMP during April 4th through 14th 2016.

Based on the inspection and the review thereafter US-FDA has concluded that the inspection is “closed” under 21CFR20.64 (d) (3) and the agency has issued an Establishment Inspection Report (EIR) for Suven facility at Pashamylaram dtd July 15, 2016.

So far Suven Life Sciences has filed 19 DMF's and 4 ANDA's from this facility which is FDA complaint under cGMP and continued after renewal inspection.

Suven Life Sciences is a Hyderabad based Life Science company is a pioneer in Contract Research and Manufacturing Services (CRAMS) since 1995 and Drug Discovery and Development Support Services (DDDSS) since 2005, a Collaborative Research Partner (CRP) in Drug Discovery and has in-house program for discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. Suven has 3 clinical stage compounds, a Phase 2 undergoing candidate SUVN-502, Phase 1 completed candidate SUVN-G3031 and Phase 1 undergoing candidate SUVN-D4010 for Alzheimer's disease and Schizophrenia. In addition to that the Company has ten (10) internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and pain.

For more information please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

Suven Life Sciences Limited

Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor Road No.5 I Avenue 7
Banjara Hills I Hyderabad – 500 034 I Telangana I India I CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com